Early safety data from a randomized, multicenter, double-blind, phase 2b study of IGV-001, an autologous cell immunotherapy, versus placebo, in newly diagnosed glioblastoma Meeting Abstract
| Authors: | Hanft, S.; Elder, B.; Giglio, P.; Wu, S. H.; Farrell, C.; Alnahhas, I.; Lee, I. Y.; Walbert, T.; Boockvar, J.; Vojnic, M.; Zacharia, B.; Aregawi, D.; Kim, L.; Schulder, M.; Ghatan, S.; Singer, S.; Correia, C. E. S.; Ramakrishna, R.; Wu, J.; Jeyapalan, S.; Magge, R.; Patel, N.; Agarwal, V.; Bhatia, A.; Brennan, C.; Evans, L.; Gill, B.; Sengupta, S.; Wong, E. T.; Amankulor, N.; Quinones-Hinojosa, A.; Neese, L.; Scott, C.; Perez-Olle, R.; Andrews, D. |
| Abstract Title: | Early safety data from a randomized, multicenter, double-blind, phase 2b study of IGV-001, an autologous cell immunotherapy, versus placebo, in newly diagnosed glioblastoma |
| Meeting Title: | 19th Meeting of the European Association of Neuro-Oncology |
| Journal Title: | Neuro-Oncology |
| Volume: | 26 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2024 Oct 17-20 |
| Meeting Location: | Glasgow, United Kingdom |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-10-01 |
| Start Page: | v67 |
| End Page: | v68 |
| Language: | English |
| ACCESSION: | WOS:001340502000221 |
| DOI: | 10.1093/neuonc/noae144.222 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P12.09 -- Abstract Citation ID: NOAE144.222 -- Source: Wos |
